title: A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.
abstract: Simple models of therapy for viral diseases such as hepatitis C virus (HCV) or human immunodeficiency virus assume that, once therapy is started, the drug has a constant effectiveness. More realistic models have assumed either that the drug effectiveness depends on the drug concentration or that the effectiveness varies over time. Here a previously introduced varying-effectiveness (VE) model is studied mathematically in the context of HCV infection. We show that while the model is linear, it has no closed-form solution due to the time-varying nature of the effectiveness. We then show that the model can be transformed into a Bessel equation and derive an analytic solution in terms of modified Bessel functions, which are defined as infinite series, with time-varying arguments. Fitting the solution to data from HCV infected patients under therapy has yielded values for the parameters in the model. We show that for biologically realistic parameters, the predicted viral decay on therapy is generally biphasic and resembles that predicted by constant-effectiveness (CE) models. We introduce a general method for determining the time at which the transition between decay phases occurs based on calculating the point of maximum curvature of the viral decay curve. For the parameter regimes of interest, we also find approximate solutions for the VE model and establish the asymptotic behavior of the system. We show that the rate of second phase decay is determined by the death rate of infected cells multiplied by the maximum effectiveness of therapy, whereas the rate of first phase decline depends on multiple parameters including the rate of increase of drug effectiveness with time.
authors.affiliation: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Conway
authors.affiliation: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America.
authors.forename: Alan S
authors.initials: AS
authors.lastname: Perelson
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019295:Computational Biology; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy / Q000821:virology*; D006801:Humans; D008954:Models, Biological; D019562:Viral Load / Q000187:drug effects*
chemical_list: D000998:Antiviral Agents
references.citation: Nature. 2004 Dec 16;432(7019):922-4
references.pmid: 15602565
references.citation: Hepatology. 2006 May;43(5):943-53
references.pmid: 16761329
references.citation: Expert Opin Drug Metab Toxicol. 2009 Mar;5(3):321-32
references.pmid: 19331594
references.citation: Hepatology. 2011 Jun;53(6):1801-8
references.pmid: 21384401
references.citation: Hepatology. 2012 Apr;55(4):1030-7
references.pmid: 22095398
references.citation: Sci Transl Med. 2010 May 5;2(30):30ra32
references.pmid: 20445200
references.citation: AIDS. 2011 Jun 1;25(9):1179-87
references.pmid: 21593619
references.citation: J Theor Biol. 2008 Sep 21;254(2):439-51
references.pmid: 18653201
references.citation: Science. 1998 Oct 2;282(5386):103-7
references.pmid: 9756471
references.citation: Curr Top Microbiol Immunol. 2013;369:321-42
references.pmid: 23463207
references.citation: Hepatology. 2009 Jan;49(1):32-8
references.pmid: 19065674
references.citation: J Biol Chem. 2007 Oct 12;282(41):29812-20
references.pmid: 17698842
references.citation: Cell Microbiol. 2013 Nov;15(11):1866-82
references.pmid: 23701235
references.citation: Hepatology. 2011 Aug;54(2):749
references.pmid: 21433039
references.citation: Antivir Ther. 2015;20(2):149-55
references.pmid: 24912382
references.citation: PLoS Comput Biol. 2013;9(3):e1002959
references.pmid: 23516348
references.citation: J Viral Hepat. 2008 May;15(5):357-62
references.pmid: 18380660
references.citation: J Theor Biol. 2004 Jan 7;226(1):95-109
references.pmid: 14637059
references.citation: Clin Pharmacol Ther. 2010 Jun;87(6):706-13
references.pmid: 20463660
references.citation: Antivir Ther. 2008;13(7):919-26
references.pmid: 19043926
references.citation: Hepatology. 2001 Nov;34(5):1012-20
references.pmid: 11679973
references.citation: Antiviral Res. 2014 May;105:64-71
references.pmid: 24583028
references.citation: Semin Liver Dis. 2003;23 Suppl 1:13-8
references.pmid: 12934163
references.citation: J Theor Biol. 2010 Dec 7;267(3):330-40
references.pmid: 20831874
references.citation: J Viral Hepat. 2008 May;15(5):379-82
references.pmid: 18266841
references.citation: Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6
references.pmid: 23431163
references.citation: Nat Rev Immunol. 2002 Jan;2(1):28-36
references.pmid: 11905835
references.citation: J Hepatol. 2012 May;56(5):1019-1024
references.pmid: 22245888
references.citation: Antivir Ther. 2014;19(2):211-20
references.pmid: 24464551
references.citation: J Hepatol. 2010 Sep;53(3):460-7
references.pmid: 20561702
references.citation: Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705
references.pmid: 15183338
references.citation: J Virol. 2006 Aug;80(15):7590-9
references.pmid: 16840338
references.citation: Hepatology. 1999 Jun;29(6):1863-9
references.pmid: 10347131